Onchocerciasis%D8%AF%D8%A7%D8%A1_%D9%83%D9%84%D8%A7%D8%A8%D9%8A%D8%A9_%D8%A7%D9%84%D8%B0%D9%86%D8%A8%D0%9E%D0%BD%D1%85%D0%BE%D1%86%D0%B5%D1%80%D0%BA%D0%BE%D0%B7%D0%B0OncocercosiCategory:OnchocerciasisOnchocerk%C3%B3zaOnchozerkose%CE%9F%CE%B3%CE%BA%CE%BF%CE%BA%CE%B5%CF%81%CE%BA%CE%AF%CE%B1%CF%83%CE%B7OnchocerciasisOnkocerkozoOncocercosis%DA%A9%D9%88%D8%B1%DB%8C_%D8%B1%D9%88%D8%AF%D8%AE%D8%A7%D9%86%D9%87JokisokeusOnchocercoseDaille_abhann%D7%A2%D7%99%D7%95%D7%95%D7%A8%D7%95%D7%9F_%D7%94%D7%A0%D7%94%D7%A8%D7%95%D7%AA%E0%A4%91%E0%A4%99%E0%A5%8D%E0%A4%95%E0%A5%8B%E0%A4%B8%E0%A4%B0%E0%A5%8D%E0%A4%95%E0%A4%BE%E0%A4%AF%E0%A4%B8%E0%A4%BF%E0%A4%B8Folyami_vaks%C3%A1gOnchocerciasisIsianya%E1%BB%8Dcha%C3%81rblindaOncocercosi%E7%B3%B8%E7%8A%B6%E8%99%AB%E7%97%87%D3%A8%D0%B7%D0%B5%D0%BD_%D1%81%D0%BE%D2%9B%D1%8B%D1%80%EA%B0%95%EB%B3%80_%EC%8B%A4%EB%AA%85%EC%A6%9D%D0%9E%D0%BD%D1%85%D0%BE%D1%86%D0%B5%D1%80%D0%BA%D0%BE%D0%B7Onchocerkiaz%C4%97%D0%9E%D0%BD%D1%85%D0%BE%D1%86%D0%B5%D1%80%D0%BA%D0%B8%D1%98%D0%B0%D0%B7%D0%B0Onkoserkiasis%E0%A4%85%E0%A4%A8%E0%A5%8D%E0%A4%95%E0%A5%8B%E0%A4%B8%E0%A4%B0%E0%A5%8D%E0%A4%B8%E0%A4%BF%E0%A4%86%E0%A4%B8%E0%A4%BF%E0%A4%B8OnchocerciaseElveblindhetOnkhocerciasisMatenda_Oyambitsa_Khungu_Komanso_MatuzaOonchooseersii%27aasiisii%E0%AC%85%E0%AC%99%E0%AD%8D%E0%AC%95%E0%AD%8B%E0%AC%B8%E0%AC%B0%E0%AD%8D%E0%AC%B8%E0%AC%BF%E0%AC%86%E0%AC%B8%E0%AC%BF%E0%AC%B8%C5%9Alepota_rzecznaOncocercoseOncocercoz%C4%83%D0%9E%D0%BD%D1%85%D0%BE%D1%86%D0%B5%D1%80%D0%BA%D0%BE%D0%B7
about
sameAs
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga DistrictOcular Changes After Ivermectin - (DOLF IVM/Oncho)IVM Alone vs ALB + IVM Against OnchocerciasisSafety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisEfficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, GhanaDetermination of a Dose of Moxidectin in Individuals < 12 Years of AgeOptimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for LiberiaOptimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and OnchocerciasisPediatric Pharmacokinetics And Safety Study Of MoxidectinStudy Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus InfectionIvermectin Treatment of Persons With Onchocerciasis-associated EpilepsyStudy Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus InfectionPrevalence of LF Infection in Districts Not Included in LF Control ActivitiesClinical Trial of Rifampin and Azithromycin for the Treatment of River BlindnessHost Response to Infection and Treatment in Filarial DiseasesIvermectin Treatment in Patients With Onchocerciasis-associated EpilepsyClinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic PatientsClinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic PatientsEvaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central AfricaSafety and Efficacy of IDA for OnchocerciasisSafety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas
P1050
P2175
Macrofilaricides and onchocerciasis control, mathematical modelling of the prospects for eliminationFeasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and SenegalOnchocerciasis in the Americas: from arrival to (near) eliminationThe Onchocerciasis Vaccine for Africa--TOVA--InitiativeDoxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasisDoxycycline plus ivermectin versus ivermectin alone for treating onchocerciasisFurther studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suraminImpact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-AfricaTreatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasisCombined Utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis (REA) in Rain forest Villages of CameroonMapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis ControlFinal report of the Conference on the eradicability of OnchocerciasisMass ivermectin treatment for onchocerciasis: lack of evidence for collateral impact on transmission of Wuchereria bancrofti in areas of co-endemicity.Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectinOnchocerciasis transmission in Ghana: the human blood index of sibling species of the Simulium damnosum complex.6) Epidemiology and Control of Guatemalan Onchocerciasis5) Review of the Biology and Ecology of Adult Blackflies in Relation to the Transmission of Onchocerciasis in Guatemala4) Preliminary Report of Japan-Guatemala Onchocerciasis Control Pilot Project3) Onchocerciasis2) Onchocerciasis2) A Guatemala-Japan Collaboration Project for Onchocerciasis Research Supported by JICA, Japan1) Guatemala-Japan Cooperative Project on Onchocerciasis Research and Control: A Review of the Technical Cooperation, Case Study Series No. 6Contribution and performance of female Community-Directed Distributors in the treatment of onchocerciasis with Ivermectin in Sub-Saharan Africa: a systematic reviewThe prevalence of epilepsy follows the distribution of onchocerciasis in a west Ugandan focusElimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.Research for new drugs for elimination of onchocerciasis in AfricaHost-parasite interaction in human onchocerciasis: identification and sequence analysis of a novel human calgranulinEpilepsy and retarded growth in a hyperendemic focus of onchocerciasis in rural western UgandaReview of epidemiological studies searching for a relationship between onchocerciasis and epilepsyOnchocerciasis-related epilepsy? Prospects at a time of uncertaintyAnti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasisVisual loss during oral diethylcarbamazine treatment for onchocerciasisThe chemotherapy of onchocerciasis. XV. Studies with albendazoleChanges in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrateOcular changes with oral and transepidermal diethylcarbamazine therapy of onchocerciasisComparison of Doxycycline, Minocycline, Doxycycline plus Albendazole and Albendazole Alone in Their Efficacy against Onchocerciasis in a Randomized, Open-Label, Pilot TrialPotential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in AfricaImmunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposureCommunity-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in CameroonAfrican Programme For Onchocerciasis Control 1995-2015: model-estimated health impact and cost
P921
Q62025120-C66A4186-F5C3-472D-8B3C-C593E67F57FCQ62817438-E445D09D-CDED-440D-BEE3-42E61A0C11A2Q63010818-F6466DE3-8F0F-4D50-B286-C51EB6A06344Q63808524-EB71C91D-D1B9-47B7-81D4-412B7ED43F4FQ63813528-0F500688-27D4-483D-9B4E-1E3542746658Q64150745-75F606AA-9F48-407F-B1DF-E1B9CEE66463Q64349241-153793C3-E2A1-4003-B086-42E34647A140Q64622922-ADC2F7F6-8319-4C56-B7B1-83550BF2B17EQ64622925-93043F8A-97B4-4BCA-8DB0-C915B2B55C44Q64683857-1BE090D0-1C4B-4142-B2D3-90FDC8649CC0Q64709859-4DB9DB46-2310-4EE8-8301-0A63FE2729CDQ64793556-F8AFA9B3-6EE9-4979-A54A-984F5A537E2DQ65537373-5B166264-5EAF-4EDE-9AE4-01F8112C7A61Q66044442-B0D9BB92-3A74-4D48-8E25-858A68FEA24AQ66059064-E9246696-329C-4E2E-ACD2-F4A65077130DQ66061426-A78876F4-51C8-4C93-9B51-16229A36CB71Q66072808-3F655D3C-905E-4AE0-9A0F-39907C59BA97Q66387267-DBAC0DC2-18F2-4940-8417-F7EB68F7A982Q66387301-C966BF38-76CF-4B86-93E3-4064F0CC0D85Q66389643-DD1BB2F1-EE2F-4FDB-A0DB-0BA82592D5C8Q79110660-FAC09A91-3179-475A-8BD2-09A40A584A62Q87931555-0AFA9122-6F6C-4839-8C81-559CDB19FE97
P1050
Q21093305-C138D74E-DC66-47C2-B123-489F285A2799Q21144535-24A63D85-1D79-4B36-8677-6E7147B8A996Q21198914-647EBBEC-F125-4C61-A933-F25A238145AFQ21562329-88358BB5-7DC5-4E8D-B92F-D538B5E980D9Q24186468-1B6F233D-3BD3-4BC8-ACA9-1D5EC84F3A25Q24194317-B0EF0FF3-0907-4E7A-8853-2B36AF6AC242Q24517506-590ACA33-6E53-42BA-B24E-F4E1150CA062Q24799577-281F37B1-D86F-4C95-89C2-FDD49C5C1790Q24799885-67A45309-D913-46F7-89AF-AD78DF8B3058Q24800164-9961BB72-2DDC-4853-B78A-AB2D09189A4FQ24800816-6718F4DB-0D7A-4047-8F64-9D52108B4FBFQ24801387-DAF93A9C-8C57-4714-AA9A-8117E5C4956CQ24813874-6075DDCD-CB24-4164-AACF-E9D58E6F72B8Q25257764-4EA631B9-F7FF-48A7-9843-3F8F62DE2741Q26315231-89DBE065-E61E-4E02-80F3-72FA71CB7BB7Q26770178-D14D5464-0EA2-4CD9-901E-CBAB2E228EFFQ26770181-5381709D-9080-4F65-AF14-1AD7339C6C3AQ26770183-E46A6BDA-BA87-443E-8BCB-8EA4D88B2BF1Q26770186-DA05EDD6-090E-4A37-AB1A-806F24BE413DQ26770188-EB093A4C-2F79-4BB2-8291-53F769C145C1Q26770194-2E8FB62B-8B99-48E7-B94B-58387C78D787Q26770198-E6BD529D-7B55-427C-B7B7-08B1C50B1DAEQ26782693-4513C6FD-A5F5-4927-987B-B0D40562F44CQ27486534-1F9615CA-39DD-49ED-BF34-DD3FE4E42713Q27692519-410A860D-C9DC-42B5-B2E5-A30EF47AFF8DQ28066402-5019AC18-AE80-44F1-B7B5-7F3068D5CBDEQ28119075-A5750D0A-8249-4E04-A537-EE7B03DFE7F2Q28239886-E1BEA227-C472-485A-A363-0D9E4C445D7BQ28256582-4016857B-0DF0-4351-89B6-16C579A3091CQ28283535-4EC196F2-7482-459E-8501-77C9A38D09AAQ28294770-1C2D4851-107C-42B4-88A0-19DE4C4A0D57Q28318522-E75A4EFE-7120-4F3E-9981-58D03C8B0BA1Q28325609-84DA5533-8ACE-40E8-9F21-09C5F1213AEDQ28367111-A5E05632-35AE-4FFF-98A7-22BF79E9C761Q28367731-C0CB3B94-6C35-4072-B033-CFBCB3F3C827Q28468411-877BC8FE-0F75-4848-8FC2-75D67692FF3CQ28468413-B0AC7EBE-8DBE-4B48-B8BE-A5AA205C8BF8Q28471815-3B7B3039-7B1F-43BA-9824-DC1F5CBFDA3CQ28476179-6F1D76F6-73DE-4A14-A8CA-E6E533A885CEQ28485398-EF32EE4A-8EA6-43FF-BAD3-319D176FAE53
P921
description
Ceguera de los ríos
@es
Human helminthiasis
@en
Krankheit
@de
Larruazaleko filariosia
@eu
az Onchocerca volvulus parazita féreg által okozott betegség
@hu
filariose cutanée, due à un nématode parasite Onchocerca volvulus
@fr
malattia infettiva causata dal ...... lariforme: Onchocerca volvulus
@it
гельмінтоз з групи філяріїдозів
@uk
מחלה
@he
寄生虫感染が病因とされる病気
@ja
name
Bệnh mù do giun chỉ Onchocerca
@vi
Daille abhann
@ga
Elveblindhet
@nb
Folyami vakság
@hu
I-Onchocerciasis
@ss
I-Onchocerciasis
@xh
Isianyaọcha
@ig
Jokisokeus
@fi
Matenda Oyambitsa Khungu Komanso Matuza
@ny
Onchocerciasis
@ak
type
label
Bệnh mù do giun chỉ Onchocerca
@vi
Daille abhann
@ga
Elveblindhet
@nb
Folyami vakság
@hu
I-Onchocerciasis
@ss
I-Onchocerciasis
@xh
Isianyaọcha
@ig
Jokisokeus
@fi
Matenda Oyambitsa Khungu Komanso Matuza
@ny
Onchocerciasis
@ak
altLabel
Cécité des rivières
@fr
Flussblindheit
@de
Flußblindheit
@de
Infection by Onchocerca volvulus (disorder)
@en
Infection by Onchocerca volvulus
@en
Onchocerca volvulus infection
@en
Onchocerca volvulus-infeksjon
@nn
Onchocerciasis
@ar
Onchocerciasis
@hu
Onchocerciasis
@it
prefLabel
Bệnh mù do giun chỉ Onchocerca
@vi
Daille abhann
@ga
Elveblindhet
@nb
Folyami vakság
@hu
I-Onchocerciasis
@ss
I-Onchocerciasis
@xh
Isianyaọcha
@ig
Jokisokeus
@fi
Matenda Oyambitsa Khungu Komanso Matuza
@ny
Onchocerciasis
@ak